Garnifit 200 Tablet SR contains Acebrophylline 200 mg, a bronchodilator and mucolytic agent used primarily in the management of respiratory conditions such as chronic obstructive pulmonary disease (COPD), asthma, and bronchitis. Acebrophylline acts by relaxing the smooth muscles of the airways, thereby facilitating easier breathing and improving airflow. Additionally, it possesses anti-inflammatory properties and helps in reducing mucus viscosity, promoting effective expectoration. The sustained-release formulation ensures a prolonged therapeutic effect, allowing for twice-daily dosing and improved patient compliance. Garnifit 200 is indicated for patients experiencing bronchospasm, airway obstruction, and excessive mucus production. It is generally well-tolerated; however, caution is advised in patients with hypersensitivity to xanthine derivatives or those with cardiovascular disorders. Common side effects may include mild gastrointestinal discomfort, headache, or nervousness. It is essential to use Garnifit 200 under medical supervision, with dosage adjustments based on clinical response and renal function. This medication should not be combined with other methylxanthines without professional guidance. Overall, Garnifit 200 Tablet SR offers a dual mechanism of action that addresses both bronchoconstriction and mucus hypersecretion, making it an effective therapeutic option in respiratory disease management.